Peripheral cardiac sympathetic hyperactivity in cardiovascular disease: Role of neuropeptides

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 305, Issue 12, 2013, Pages

  Shanks, Julia ^a   Herring, Neil ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Autonomic nervous system; Cardiac; Hypertension; Myocardial infarction; Neuropeptide Y

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN II; CALCIUM; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOTHELIN 1; GALANIN; NEUROPEPTIDE; NEUROPEPTIDE Y; NORADRENALIN; PROTEIN KINASE C; RYANODINE RECEPTOR;

ACETYLCHOLINE RELEASE; ACUTE CORONARY SYNDROME; ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; ADRENERGIC TRANSMISSION; AUTONOMIC NERVOUS SYSTEM; BRADYCARDIA; BRUGADA SYNDROME; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CHOLINERGIC NERVE; CHOLINERGIC TRANSMISSION; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY BLOOD FLOW; DISEASE EXACERBATION; DORSAL ROOT; ENDOPLASMIC RETICULUM; ESSENTIAL HYPERTENSION; EXTRACELLULAR SPACE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HEART RATE VARIABILITY; HEART RIGHT VENTRICLE DYSPLASIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; IN VITRO STUDY; MENTAL STRESS; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR INTERACTION; MUSCLE SYMPATHETIC NERVE ACTIVITY; NODOSE GANGLION; NONHUMAN; NORADRENALIN BLOOD LEVEL; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL NERVOUS SYSTEM; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NERVE CELL; SOLITARY TRACT NUCLEUS; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STELLATE GANGLION; SUPERIOR CERVICAL GANGLION; SYMPATHETIC GANGLION; SYMPATHETIC NERVE; SYMPATHETIC TONE; TACHYCARDIA; THERMODILUTION; VAGUS NERVE; VASCULAR SMOOTH MUSCLE;

AUTONOMIC NERVOUS SYSTEM; CARDIAC; HYPERTENSION; MYOCARDIAL INFARCTION; NEUROPEPTIDE Y;

ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; GALANIN; HEART; HYPERTENSION; NEUROPEPTIDE Y; NEUROPEPTIDES; RATS; RATS, INBRED SHR; SYMPATHETIC NERVOUS SYSTEM;

EID: 84890382331     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00118.2013     Document Type: Review

References (124)

1. Adrian TE, Gu J, Allen JM, Tatemoto K, Polak JM, Bloom SR. Neuropeptide Y in the human male genital tract. Life Sci 35: 2643-2648, 1984.
2. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans: evidence from direct intraneural recordings. Hypertension 14: 177-183, 1989.
3. Armour JA. Potential clinical relevance of the "little brain" on the mammalian heart. Exp Physiol 93: 165-176, 2008.
4. Boudaka A, Worl J, Shiina T, Shimizu Y, Takewaki T, Neuhuber WL. Galanin modulates vagally induced contractions in the mouse oesophagus. Neurogastroenterol Motil 21: 180-188, 2009.
5. Bowers CW, Zigmond RE. Localization of neurons in the rat superior cervical ganglion that project into different postganglionic trunks. J Comp Neurol 185: 381-391, 1979.
6. Burnstock G. Autonomic neurotransmission: 60 years since sir Henry Dale. Annu Rev Pharmacol Toxicol 49: 1-30, 2009.
7. Burnstock G. Cotransmission. Curr Opin Pharmacol 4: 47-52, 2004.
8. Burnstock G. Determinants of signal transmission in healthy and diseased autonomic neuromuscular junctions. Diabet Med, 10, Suppl 2: 64S-69S, 1993.
9. Burnstock G. Do some nerve cells release more than one transmitter? Neuroscience 1: 239-248, 1976.
10. Burnstock G. The fifth Heymans memorial lecture-Ghent, February 17, 1990. Cotransmission. Arch Int Pharmacodyn Ther 304: 7-33, 1990.
11. Burnstock G. Purinergic receptors in the nervous system. In: Current Topics in Membranes, edited by EM S. San Diego, CA: Academic, 2003, p. 307-368.
12. Cabassi A, Vinci S, Quartieri F, Moschini L, Borghetti A. Norepi-nephrine reuptake is impaired in skeletal muscle of hypertensive rats in vivo. Hypertension 37: 698-702, 2001.
13. Cassaglia PA, Griffiths RI, Walker AM. Sympathetic nerve activity in the superior cervical ganglia increases in response to imposed increases in arterial pressure. Am J Physiol Regul Integr Comp Physiol 294: R1255-R1261, 2008.
14. Cassis LA, Stitzel RE, Head RJ. Hypernoradrenergic innervation of the caudal artery of the spontaneously hypertensive rat: an influence upon neuoeffector mechanisms. Pharmacol Exp Therap 234: 792-803, 1985.
15. Cardiac Insufficiency Bisoprolol Study. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353: 9-13, 1999.
16. Clarke JG, Davies GJ, Kerwin R, Hackett D, Larkin S, Dawbarn D, Lee Y, Bloom SR, Yacoub M, Maseri A. Coronary artery infusion of neuropeptide Y in patients with angina pectoris. Lancet 1: 1057-1059, 1987.
17. Cohn PF. When is concern about silent myocardial ischemia justified? Ann Intern Med 100: 597-599, 1984.
18. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med 341: 1351-1357, 1999.
19. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429-1435, 1987.
20. Cuculi F, De Caterina AR, Kharbanda RK, Banning AP. Optimal reperfusion in ST-elevation myocardial infarction-the role of the coronary microcirculation. Swiss Med Wkly 141: w13313, 2011.
21. Cuculi F, Herring N, De Caterina AR, Banning AP, Prendergast BD, Forfar JC, Choudhury RP, Channon KM, Kharbanda RK. Relationship of plasma neuropeptide Y with angiographic, electrocardiographic and coronary physiology indices of reperfusion during ST elevation myocardial infarction. Heart 99: 1198-1203, 2013.
22. Danson EJ, Paterson DJ. Enhanced neuronal nitric oxide synthase expression is central to cardiac vagal phenotype in exercise-trained mice. J Physiol 546: 225-232, 2003.
23. Davrath LR, Goren Y, Pinhas I, Toledo E, Akselrod S. Early auto-nomic malfunction in normotensive individuals with a genetic predisposition to essential hypertension. Am J Physiol Heart Circ Physiol 285: H1697-H1704, 2003.
24. Dawson TA, Li D, Woodward T, Barber Z, Wang L, Paterson DJ. Cardiac cholinergic NO-cGMP signaling following acute myocardial infarction and nNOS gene transfer. Am J Physiol Heart Circ Physiol 295: H990-H998, 2008.
25. Degtyarenko AM, Kaufman MP. Barosensory cells in the nucleus tractus solitarius receive convergent input from group III muscle affer-ents and central command. Neuroscience 140: 1041-1050, 2006.
26. Edvinsson L, Ekblad E, Hakanson R, Wahlestedt C. Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br J Pharmacol 83: 519-525, 1984.
27. Edvinsson L, Ekman R, Thulin T. Increased plasma levels of neuro-peptide Y-like immunoreactivity and catecholamines in severe hypertension remain after treatment to normotension in man. Regul Pept 32: 279-287, 1991.
28. Erlinge D, Burnstock G. P2 receptors in cardiovascular regulation and disease. Purinergic Signal 4: 1-20, 2008.
29. Esler M, Jennings G, Biviano B, Lambert G, Hasking G. Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol, 8 Suppl 5: S39-43, 1986.
30. Esler M, Jennings G, Korner P, Blombery P, Sacharias N, Leonard P. Measurement of total and organ-specific norepinephrine kinetics in humans. Am J Physiol Endocrinol Metab 247: E21-E28, 1984.
31. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376: 1903-1909, 2010.
32. Fisher JP, Paton JF. The sympathetic nervous system and blood pressure in humans: implications for hypertension. J Hum Hypertens 26: 463-475, 2012.
33. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 2: 57-66, 1986.
34. Flaa A, Mundal HH, Eide I, Kjeldsen S, Rostrup M. Sympathetic activity and cardiovascular risk factors in young men in the low, normal, and high blood pressure ranges. Hypertension 47: 396-402, 2006.
35. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 54: 690-697, 2009.
36. Greenwood JP, Stoker JB, Mary DASG. Single-unit sympathetic discharge: quantitative assesment in human hypertensive disease. Circ Res 100: 1305-1310, 1999.
37. Han C, Wang XA, Fiscus RR, Gu J, McDonald JK. Changes in cardiac neuropeptide Y after experimental myocardial infarction in rat. Neurosci Lett 104: 141-146, 1989.
38. Heaton DA, Li D, Almond SC, Dawson TA, Wang L, Channon KM, Paterson DJ. Gene transfer of neuronal nitric oxide synthase into intracardiac ganglia reverses vagal impairment in hypertensive rats. Hypertension 49: 380-388, 2007.
39. Herring N, Cranley J, Lokale MN, Li D, Shanks J, Alston EN, Girard BM, Carter E, Parsons RL, Habecker BA, Paterson DJ. The cardiac sympathetic co-transmitter galanin reduces acetylcholine release and vagal bradycardia: implications for neural control of cardiac excitability. J Mol Cell Cardiol 52: 667-676, 2012.
40. Herring N, Lee CW, Sunderland N, Wright K, Paterson DJ. Prava-statin normalises peripheral cardiac sympathetic hyperactivity in the spontaneously hypertensive rat. J Mol Cell Cardiol 50: 99-106, 2011.
41. Herring N, Lokale MN, Danson EJ, Heaton DA, Paterson DJ. Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway. J Mol Cell Cardiol 44: 477-485, 2008.
42. Herring N, Paterson DJ. Adaption and responses: myocardiacl inner-vations and neural control. In: Muscle Fundamental Biology and Mechanisms of Disease, edited by Hill JA and Olsen EN. London: Academic, 2012, vol. 1, part 2, chapt. 20, p. 275-284.
43. Herring N, Paterson DJ. Neuromodulators of peripheral cardiac sym-patho-vagal balance. Exp Physiol 94: 46-53, 2009.
44. Hulting J, Sollevi A, Ullman B, Franco-Cereceda A, Lundberg JM. Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res 24: 102-108, 1990.
45. Jeong YB, Kim TH, Roh YJ, Choi IC, Suh JH. Comparison of uncalibrated arterial pressure waveform analysis with continuous ther-modilution cardiac output measurements in patients undergoing elective off-pump coronary artery bypass surgery. J Cardiothorac Vasc Anesth 24: 767-771, 2010.
46. Jordan J, Heusser K, Brinkmann J, Tank J. Electrical carotid sinus stimulation in treatment resistant arterial hypertension. Auton Neurosci 172: 31-36, 2012.
47. Kimura S, Miura Y, Adachi M, Nezu M, Toriyabe S, Sugawara T, Ishizuka Y, Noshiro T, Takahashi M. The effect of sodium depletion on plasma norepinephrine kinetics in patients with essential hypertension. Jpn Circ J 47: 1232-1241, 1983.
48. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myo-cardial infarction. Am J Cardiol 59: 256-262, 1987.
49. Kokubo M, Uemura A, Matsubara T, Murohara T. Noninvasive evaluation of the time course of change in cardiac function in spontaneously hypertensive rats by echocardiography. Hypertens Res 28: 601-609, 2005.
50. Komolova M, Friberg P, Adams MA. Altered vascular resistance properties and acute pressure-natriuresis mechanism in neonatal and weaning spontaneously hypertensive rats. Hypertension 59: 979-984, 2012.
51. Kowalyk S, Veith R, Boyle M, Taborsky GJ Jr. Liver releases galanin during sympathetic nerve stimulation. Am J Physiol Endocrinol Metab 262: E671-E678, 1992.
52. Kummer W. Galanin- and neuropeptide Y-like immunoreactivities coexist in paravertebral sympathetic neurones of the cat. Neurosci Lett 78: 127-131, 1987.
53. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 351: 478-484, 1998.
54. Labrakakis C, Tong CK, Weissman T, Torsney C, MacDermott AB. Localization and function of ATP and GABAA receptors expressed by nociceptors and other postnatal sensory neurons in rat. J Physiol 549: 131-142, 2003.
55. Lamping KG, Chilian WM, Eastham CL, Marcus ML. Coronary microvascular response to exogenously administered and endogenously released acetylcholine. Microvasc Res 43: 294-307, 1992.
56. Langewitz W, Ruddel H, Schachinger H. Reduced parasympathetic cardiac control in patients with hypertension at rest and under mental stress. Am Heart J 127: 122-128, 1994.
57. Lee RMKW, Triggle CR, Cheung DWT, Coughlin MD. Structural and functional consequences of neonatal sympathectomy on the blood vessels of spontaneously hypertensive rats. Hypertension 10: 328-338, 1987.
58. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561-1566, 1990.
59. Li D, Lee CW, Buckler KJ, Parekh A, Herring N, Paterson DJ. Abnormal intracellular calcium homeostasis in sympathetic neurons from young prehypertensive rats. Hypertension 59: 642-649, 2012.
60. Li D, Nikiforova N, Lu CJ, Wannop K, McMenamin M, Lee CW, Buckler KJ, Paterson DJ. Targeted neuronal nitric oxide synthase transgene delivery into stellate neurons reverses impaired intracellular calcium transients in prehypertensive rats. Hypertension 61: 202-207, 2013.
61. Li D, Wang L, Lee CW, Dawson TA, Paterson DJ. Noradrenergic cell specific gene transfer with neuronal nitric oxide synthase reduces cardiac sympathetic neurotransmission in hypertensive rats. Hypertension 50: 1-6, 2007.
62. Lindh B, Staines W, Hokfelt T, Terenius L, Salvaterra PM. Immu-nohistochemical demonstration of choline acetyltransferase-immunore-active preganglionic nerve fibers in guinea pig autonomic ganglia. Proc Natl Acad Sci USA 83: 5316-5320, 1986.
63. Lubbe WF, Podzuweit T, Opie LH. Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J Am Coll Cardiol 19: 1622-1633, 1992.
64. Lucini D, Mela GS, Malliani A, Pagani M. Impairment in cardiac autonomic regulation preceding arterial hypertension in humans: insights from spectral analysis of beat-by-beat cardiovascular variability. Circulation 106: 2673-2679, 2002.
65. Malliani A, Pagani M, Bergamaschi M. Positive feedback sympathetic reflexes and hypertension. Am J Cardiol 44: 860-865, 1979.
66. Malliani A, Schwartz PJ, Zanchetti A. A sympathetic reflex elicited by experimental coronary occlusion. Am J Physiol 217: 703-709, 1969.
67. Manabe N, Foldes FF, Torocsik A, Nagashima H, Goldiner PL, Vizi ES. Presynaptic interaction between vagal and sympathetic innervation in the heart: modulation of acetylcholine and noradrenaline release. J Auton Nerv Syst 32: 233-242, 1991.
68. Mayer AF, Schroeder C, Heusser K, Tank J, Diedrich A, Schmieder RE, Luft FC, Jordan J. Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension 48: 120-126, 2006.
69. McDermott BJ, Bell D. NPY and cardiac diseases. Curr Top Med Chem 7: 1692-1703, 2007.
70. Merighi A. Costorage and coexistence of neuropeptides in the mammalian CNS. Prog Neurobiol 66: 161-190, 2002.
71. Mohan RM, Heaton DA, Danson EJ, Krishnan SP, Cai S, Channon KM, Paterson DJ. Neuronal nitric oxide synthase gene transfer promotes cardiac vagal gain of function. Circ Res 91: 1089-1091, 2002.
72. Nash MP, Thornton JM, Sears CE, Varghese A, O'Neill M, Paterson DJ. Ventricular activation during sympathetic imbalance and its computational reconstruction. J Appl Physiol 90: 287-298, 2001.
73. Ng GA, Brack KE, Patel VH, Coote JH. Autonomic modulation of electrical restitution, alternans and ventricular fibrillation initiation in the isolated heart. Cardiovasc Res 73: 750-760, 2007.
74. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol 54: 281-292, 2009.
75. Niccoli G, Giubilato S, Russo E, Spaziani C, Leo A, Porto I, Leone AM, Burzotta F, Riondino S, Pulcinelli F, Biasucci LM, Crea F. Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. Eur Heart J 29: 1843-1850, 2008.
76. Niccoli G, Lanza GA, Shaw S, Romagnoli E, Gioia D, Burzotta F, Trani C, Mazzari MA, Mongiardo R, De Vita M, Rebuzzi AG, Luscher TF, Crea F. Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascular-ization. Eur Heart J 27: 1793-1798, 2006.
77. Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, Baig W, Flapan AD, Cowley A, Prescott RJ, Neilson JM, Fox KA. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 98: 1510-1516, 1998.
78. Noll G, Wenzel RR, Schneider M, Oesch V, Binggeli C, Shaw S, Weidmann P, Luscher TF. Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation 93: 866-869, 1996.
79. Opie LH, Clusin WT. Cellular mechanism for ischemic ventricular arrhythmias. Annu Rev Med 41: 231-238, 1990.
80. Parker LK, Shanks JA, Kennard JAG, Brain KL. Dynamic monitoring of NET activity in mature murine sympathetic terminals using a fluorescent substrate. Br J Pharmacol 159: 797-807, 2010.
81. Paton JF, Sobotka PA, Fudim M, Engleman ZJ, Hart EC, McBryde FD, Abdala AP, Marina N, Gourine AV, Lobo M, Patel N, Burchell A, Ratcliffe L, Nightingale A. The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases. Hypertension 61: 5-13, 2013.
82. Pedrazzini T, Seydoux J, Kunstner P, Aubert JF, Grouzmann E, Beermann F, Brunner HR. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med 4: 722-726, 1998.
83. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, and et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction Results of the survival and ventricular enlargement trial The SAVE Investigators. N Engl J Med 327: 669-677, 1992.
84. Pirola FT, Potter EK. Vagal action on atrioventricular conduction and its inhibition by sympathetic stimulation and neuropeptide Y in anaesthetised dogs. J Auton Nerv Syst 31: 1-12, 1990.
85. Pons J, Lee EW, Li L, Kitlinska J. Neuropeptide Y: multiple receptors and multiple roles in cardiovascular diseases. Curr Opin Investig Drugs 5: 957-962, 2004.
86. Potter EK. Cardiac vagal action and plasma levels of neuropeptide Y following intravenous injection in the dog. Neurosci Lett 77: 243-247, 1987.
87. Potter EK, McCloskey DI. Peripheral inhibition of cardiac vagal action by sympathetic adrenergic stimulation. Proc Australiasian Soc Clin Experimental Pharmacol 13: 99P, 1982.
88. Potter EK, Smith-White MA. Galanin modulates cholinergic neu-rotransmission in the heart. Neuropeptides 39: 345-348, 2005.
89. Reid JV, Ito BR, Huang AH, Buffington CW, Feigl EO. Parasympa-thetic control of transmural coronary blood flow in dogs. Am J Physiol Heart Circ Physiol 249: H337-H343, 1985.
90. Rittenhouse AR, Zigmond RE. Role of N- and L-type calcium channels in depolarization-induced activation of tyrosine hydroxylase and release of norepinephrine by sympathetic cell bodies and nerve terminals. J Neurobiol 40: 137-148, 1999.
91. Rumantir MS, Kaye DM, Jennings GL, Vaz M, Hastings JA, Esler MD. Phenotypic evidence of faulty neuronal norepinephrine reuptake in essential hypertension. Hypertension 36: 824-829, 2000.
92. Salo LM, Campos RR, McAllen RM. Differential control of cardiac functions by the brain. Clin Exp Pharmacol Physiol 33: 1255-1258, 2006.
93. Saura J, Kettler R, Da Prada M, Richards JG. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci 12: 1977-1999, 1992.
94. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108: 560-565, 2003.
95. Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, Hastings JA, Aggarwal A, Esler MD. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension 43: 169-175, 2004.
96. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 361: 932-934, 2009.
97. Schwartz PJ. Vagal stimulation for heart diseases: from animals to men. An example of translational cardiology. Circ J 75: 20-27, 2011.
98. Schwertfeger E, Klein T, Vonend O, Oberhauser V, Stegbauer J, Rump LC. Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y2-receptors. Naunyn Schmiedebergs Arch Pharmacol 369: 455-461, 2004.
99. Sendeski MM, Consolim-Colombo FM, Leite CC, Rubira MC, Lessa P, Krieger EM. Increased sympathetic nerve activity correlates with neurovascular compression at the rostral ventrolateral medulla. Hypertension 47: 988-995, 2006.
100. Shah SH, Freedman NJ, Zhang L, Crosslin DR, Stone DH, Haynes C, Johnson J, Nelson S, Wang L, Connelly JJ, Muehlbauer M, Gins-burg GS, Crossman DC, Jones CJ, Vance J, Sketch MH, Granger CB, Newgard CB, Gregory SG, Goldschmidt-Clermont PJ, Kraus WE, Hauser ER. Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis. PLoS Genet 5: e1000318, 2009.
101. Shanks J, Mane S, Ryan R, Paterson DJ. Ganglion-specific impairment of the norepinephrine transporter in the hypertensive rat. Hypertension 61: 187-193, 2013.
102. Shanks J, Manou-Stathopoulou S, Lu CJ, Paterson DJ, Herring N. Periferal cardiac sympathetic dysfunction in the prehypertensive sponta-neoulsy hypertensive rat. FASEB 26: 1091.21, 2012.
103. Shanks J, Manou-Stathopoulou S, Lu CJ, Li D, Paterson DJ, Herring N. Cardiac sympathetic dysfunction in the prehypertensive spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 305: H980- H986, 2013.
104. Smith-White MA, Hardy TA, Brock JA, Potter EK. Effects of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors at peripheral neuroeffector junctions. Br J Pharmacol 132: 861-868, 2001.
105. Smith-White MA, Herzog H, Potter EK. Cardiac function in neuro-peptide Y Y4 receptor-knockout mice. Regul Pept 110: 47-54, 2002.
106. Smith-White MA, Iismaa TP, Potter EK. Galanin and neuropeptide Y reduce cholinergic transmission in the heart of the anaesthetised mouse. Br J Pharmacol 140: 170-178, 2003.
107. Strata P, R. Harvey Dale's principle. Brain Res Bull 50: 349-350, 1999.
108. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376: 875-885, 2010.
109. Takeda K, Nakata T, Takesako T, Itoh H, Hirata M, Kawasaki S, Hayashi J, Oguro M, Sasaki S, Nakagawa M. Sympathetic inhibition and attenuation of spontaneous hypertension by PVN lesions in rats. Brain Res 543: 296-300, 1991.
110. Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic poly-peptide. Nature 296: 659-660, 1982.
111. Tatemoto K, Rokaeus A, Jornvall H, McDonald TJ, Mutt V. Galanin: a novel biologically active peptide from porcine intestine. FEBS Lett 164: 124-128, 1983.
112. Tseng CJ, Robertson D, Light RT, Atkinson JR, Robertson RM. Neuropeptide Y is a vasoconstrictor of human coronary arteries. Am J Med Sci 296: 11-16, 1988.
113. Ullman B, Hulting J, Lundberg JM. Prognostic value of plasma neuropeptide-Y in coronary care unit patients with and without acute myocardial infarction. Eur Heart J 15: 454-461, 1994.
114. Warner MR, Levy MN. Inhibition of cardiac vagal effects by neurally released and exogenous neuropeptide Y. Circ Res 65: 1536-1546, 1989.
115. Warner MR, Levy MN. Sinus and atrioventricular nodal distribution of sympathetic fibers that contain neuropeptide Y. Circ Res 67: 713-721, 1990.
116. Warner MR, Senanayake PD, Ferrario CM, Levy MN. Sympathetic stimulation-evoked overflow of norepinephrine and neuropeptide Y from the heart. Circ Res 69: 455-465, 1991.
117. Westfall TC. Neuropeptide Y and sympathetic control of vascular tone in hypertension. EXS: 89-103, 2006.
118. Wetzel GT, Goldstein D, Brown JH. Acetylcholine release from rat atria can be regulated through an alpha 1-adrenergic receptor. Circ Res 56: 763-766, 1985.
119. Wu LJ, Li Y, Xu TL. Co-release and interaction of two inhibitory co-transmitters in rat sacral dorsal commissural neurons. Neuroreport 13: 977-981, 2002.
120. Zamotrinsky AV, Kondratiev B, de Jong JW. Vagal neurostimulation in patients with coronary artery disease. Auton Neurosci 88: 109-116, 2001.
121. Zipes D.P, Jalife J. Cardiac Electrophysiology: From Cell to Bedside (5th Ed.). Philadelphia, PA: Saunders Elsevier, 2009.
122. Zucker IH, Schultz HD, Li YF, Wang Y, Wang W, Patel KP. The origin of sympathetic outflow in heart failure: the roles of angiotensin II and nitric oxide. Prog Biophys Mol Biol 84: 217-232, 2004.
123. Zugck C, Lossnitzer D, Backs J, Kristen A, Kinscherf R, Haass M. Increased cardiac norepinephrine release in spontaneously hypertensive rats: role of presynaptic alpha-2A adrenoceptors. Hypertension 21: 1363- 1369, 2003.
124. Zukowska Z, Grant DS, Lee EW. Neuropeptide Y: a novel mechanism for ischemic angiogenesis. Trends Cardiovasc Med 13: 86-92, 2003.